VOGLI TRIO 0.2 (Voglibose (0.2mg) + Metformin (500mg) + Gliclazide (80mg))

Vogli Trio 0.2 Tablet is classified as an anti-diabetic medication and is specifically indicated for the management of type 2 diabetes mellitus in adult patients. This formulation combines various active ingredients to support the regulation of blood sugar levels in individuals diagnosed with diabetes. It is essential to administer this medication alongside food to optimize its effectiveness. Consistency in dosing is crucial; therefore, it is advisable to take the tablet at the same time each day as directed by your healthcare professional. The appropriate dosage will be determined by your physician and may be adjusted based on the effectiveness of treatment and monitoring of your blood glucose levels. It is important to continue using this medication even if you perceive an improvement in your health or if your blood sugar appears to be well-controlled. Abrupt cessation of the drug without medical consultation can lead to elevated blood sugar levels, increasing the risk of serious complications such as kidney impairment, vision loss, nerve damage, and amputations. The management of diabetes should also involve adherence to a balanced diet, regular physical activity, and weight management as advised by a healthcare provider. Notably, one of the frequent adverse effects associated with Vogli Trio 0.2 Tablet is hypoglycemia or low blood sugar. Patients should be aware of the symptoms of hypoglycemia, which can include sweating, dizziness, headache, and trembling, and understand how to respond appropriately. To mitigate the risk of hypoglycemia, it is recommended to maintain regular meal schedules and carry a fast-acting carbohydrate source, like sugary snacks or fruit juice. Alcohol consumption may exacerbate the risk of hypoglycemia and should generally be avoided. Other reported side effects of this medication may include alterations in taste, nausea, vomiting, diarrhea, abdominal discomfort, headaches, swelling, blurred vision, and potential weight gain. Caution is advised against using this medication in individuals with type 1 diabetes, diabetic ketoacidosis, or severe renal or hepatic conditions. Prior to initiating treatment, it is necessary to inform your doctor of any history of cardiovascular disease, as this may influence the appropriateness of Vogli Trio 0.2. Pregnant or nursing women should seek medical advice before starting this treatment, and regular monitoring of blood glucose, as well as periodic blood tests to assess blood cell counts and liver function, may be recommended.